sur Sandoz Group AG (isin : CH1243598427)
Sandoz Secures EU Approval for Ondibta® in Diabetes Treatment
On January 14, 2026, Sandoz Group AG announced the European Commission's approval for Ondibta® (insulin glargine). This biosimilar offers treatments akin to the reference medicine, Lantus® SoloStar®. Approved for all age groups starting from two, it matches the safety and efficacy of its reference.
Ondibta®, developed by Gan & Lee Pharmaceuticals, is slated for a 2027 launch. Its entry is expected to boost insulin access, offering affordable treatment options across Europe. This development is a strategic step for Sandoz, aligning with its aim to make impactful biologic medicines accessible.
Diabetes remains a critical global health issue, affecting millions and escalating healthcare costs. Sandoz's latest approval not only reinforces its market position in diabetes care but also highlights its leadership in biosimilars.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Sandoz Group AG